Search
AMGN-0007
go.drugbank.com/drugs/DB06511ExperimentalRecombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.
Rabies virus inactivated antigen, B
go.drugbank.com/drugs/DB10062ApprovedInvestigationalInactivated rabies virus antigen B is a component of rabies vaccines used for pre- and post-exposure prophylaxis against rabies.[L12795]
Cerulenin
go.drugbank.com/drugs/DB01034ExperimentalCerulenin is an antifungal agent whose activity interferes with or otherwise acts to prevent the formation of fatty acids and sterols.
Maridebart Cafraglutide
go.drugbank.com/drugs/DB19339Investigational, With or Without Type 2 Diabetes Mellitus). … Maridebart Cafraglutide is under investigation in clinical trial NCT05669599 (Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity
Phenamazoline
go.drugbank.com/drugs/DB19509ExperimentalThe usage of the INN stem '-azoline' in the name indicates that Phenamazoline is a antihistaminic or local vasoconstrictor, antazoline derivative. … Phenamazoline has a monoisotopic molecular weight of 175.11 Da.
Tinazoline
go.drugbank.com/drugs/DB20310ExperimentalThe usage of the INN stem '-azoline' in the name indicates that Tinazoline is a antihistaminic or local vasoconstrictor, antazoline derivative. … Tinazoline has a monoisotopic molecular weight of 217.07 Da.
Nemazoline
go.drugbank.com/drugs/DB21115ExperimentalThe usage of the INN stem '-azoline' in the name indicates that Nemazoline is a antihistaminic or local vasoconstrictor, antazoline derivative. … Nemazoline has a monoisotopic molecular weight of 243.03 Da.
Tribromsalan
go.drugbank.com/drugs/DB20138ApprovedWithdrawnTribromsalan has a monoisotopic molecular weight of 446.81 Da.
Arbaclofen
go.drugbank.com/drugs/DB08891InvestigationalArbaclofen, or STX209, is the R-enantiomer of baclofen.
ACA 125
go.drugbank.com/drugs/DB05489InvestigationalAntiidiotypic antibodies bearing the internal image of an antigen expressed on the surface of the tumor are suited to this approach. … This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of the host to respond against tumor cells.